Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3201 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Urigen closes Phase II interstitial cystitis trial

The URG101-104 study was a pharmacodynamic and safety study investigating the treatment of painful bladder syndrome or interstitial cystitis (PBS/IC). The cross-over design utilized provided sufficient power to

Varian acquires Oxford Diffraction

Varian acquired Oxford Diffraction for approximately $37 million in cash and assumed net debt. The transaction also includes an opportunity for additional purchase price payments over three years,